

MICROBIOME

WORLD CONGRESS

Americas 2017

November 7-8, 2017, Capital Hilton, Washington, DC

Successfully commercializing
microbiome-based diagnostics,
therapeutics, adjunct therapies and
direct-to-consumer services and
products.

www.terrapinn.com/microbiome17

Created by
SPARK SOMETHING
TERRAPINN 



Jack Gilbert

Presentation

The new paradigm of treatment: Understanding the relationship between ecology and medicine in unlocking the potential of the microbiome

- What is the current state of the field and how have new techniques in molecular biology enabled us to probe the microbiome and better understand its diversity and biological significance?
- When dealing with living organisms- How does microbial ecology differ from classical drug therapies, and classical medical statistics?
- What areas have we seen greatest progress and how do we avoid overselling microbiome potential and current state before we have solid evidence of translational capacity?

Jack Gilbert, Faculty Director, **The Microbiome Center** Professor, Department of Surgery, **The University of Chicago** Senior Scientist (Adjunct), **the Marine Biological Laboratory**, Group Leader in Microbial Ecology, **Argonne National Laboratory**

Our story

The study of Microbiome is rapidly evolving into both viable treatments and associated commercial opportunities. The inaugural **Microbiome World Congress Americas 2017** will bring together leading pharma, biotechs, academic researchers, and their partners to Washington DC in order to discuss how to successfully commercialize microbiome-based diagnostics, therapeutics, adjunct therapies and direct-to-consumer services and products.

With leading researchers like **Jack Gilbert of The University of Chicago**, and **Elaine Hsiao of UCLA**, alongside the **FDA** and leading pharma and biotechs such as **Janssen**, **Pfizer**, **Seres Therapeutics** and **Enterome**, this will be a forum for the entire community to come together to learn, network and create the partnerships necessary to develop microbiome-based diagnostics and therapies. At the same time, academic researchers will gain key insights into how to develop and commercialize their research.

Throughout our congress we have assembled leaders from academia to pharma to pinpoint leading issues in regulation, bioinformatics, and financing of microbiome therapies. Our cutting edge **Pitch and Partner** program will serve as a platform to biotechs looking for funding and partnerships, highlighting promising microbiome investment opportunities for investors and big pharma.

Furthermore, our **Microbiome World Congress Americas** is co-located with the industry leading **Precision Medicine Congress USA**, to find synergy in this next generation of creating truly personalized treatments that will change the future of medicine and health as we know it.



The earlier you book, the more you save! Visit www.terrapiinn.com/microbiomeUS

Game Changers

This landmark congress is bringing together some of microbiomes most important pioneers – from Paul Carlson Jr, the FDA's first co-chair on FMT, to Elaine Hsiao, whose influential work in the gut-brain axis catapulted her into the 2014 Forbes "30 Under 30 in Science and Healthcare" list. These luminaries are gathering at the World Microbiome Congress to tell the world how they got there – and where they're going next.

Spearheading the nascent commercialization of microbiome are our expert speakers from established pharma and the newest, most cutting-edge biotechs. Pfizer, Janssen, and GSK will show attendees how to maximize the therapeutic potential of emerging platforms. On the biotech side, speakers range from Rodolphe Clerval who brought finance and microbiome together, to Matt Henn, whose expertise has made Seres Therapeutics one of Microbiome's biggest early players.

SCIENCE



Paul E. Carlson Jr., Ph.D., Principal investigator, Laboratory of Mucosal Pathogens and Cellular Immunology, **CBER/OVRR, U.S. Food and Drug Administration**



Elaine Hsiao, Ph.D., Principal Investigator, Hsiao Lab, **UCLA**



Marina R. Walther-Antonio, Ph.D., Assistant Professor of Surgery, **Mayo Clinic**



Jose C. Clemente, Ph.D., Assistant Professor, **Department of Genetics and Genomic Sciences and the Immunology Institute at the Icahn School of Medicine at Mount Sinai**



Suzanne Devkota, Ph.D., Assistant Professor, Director Microbiome Research at F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, **David Geffen School of Medicine, UCLA**



Mehrdad Yazdani, Ph.D., Machine Learning and Data Scientist, **Open Medicine Institute, California Institute for Telecommunications and Information Technology, UC San Diego**

COMMERCIAL



Nikola Trbovic, Ph.D., Director R&D Technology Strategy, **Pfizer**



Carrie (McManus) Brodmerkel, Head, Immunology Biomarkers, Immunology Therapeutic Area, **Janssen R&D**



Jim Brown, B.Sc., M.Sc., Ph.D., Director, Computational Biology, Senior Fellow, **GlaxoSmithKline**



Matt Henn, PhD, Senior VP, Head of Drug Discovery and Bioinformatics, **Seres Therapeutics**



Rodolphe Clerval, Chief Business Officer, **Enterome Bioscience**



Alex Scheeler, Senior Regulatory Affairs Associate, **OpenBiome**

2017 Speakers

PHARMA AND BIOTECHS



Nikola Trbovic

Director R&D Technology Strategy, **Pfizer**



Carrie (McManus) Brodmerkel

Head, Immunology Biomarkers, Immunology Therapeutic Area, **Janssen R&D**



Kathleen Basmadjian

Sr Director, Global Regulatory Policy & Intelligence, Global Regulatory Affairs, **Janssen R&D**



Jim Brown

Director in Computational Biology, **GlaxoSmithKline**



Matt Henn

Sr. VP, Head of Drug Discovery and Bioinformatics, **Seres Therapeutics**



Rodolphe Clerval

Chief Business Officer, **Enterome**



Micah Mackison

VP Corporate Development and Strategy, **Assembly Biosciences**



Aoife Brennan

Chief Medical Officer, **Synlogic**



Henry Rath

VP Business Development, **Seres Therapeutics**



Alex Scheeler

Senior Regulatory Affairs Associate, **OpenBiome**



Nikole Kimes

Founder, Vice President, **Siolta Therapeutics**



Jonathan Scheiman

Co-Founder CEO, **FitBiomics Inc.**



Travis Whitfill

Co-Founder, **Azitra Inc.**



Zach Charlop-Powers

Scientist, **Lodo Therapeutics**



James Mutamba

Co-Founder, **Commense Health**



Michael Kaleko

Senior Vice President, Research & Development, **Synthetic Biologics**



Barry Goldman

Vice President, Discovery, **Indigo Agriculture**



Lilly Ting

Associate, **PureTech Health**, Head of Science, **CommenSe Health**

2017 Speakers

RESEARCH LEADERS



Jack Gilbert

Faculty Director, **The Microbiome Center**



Elaine Hsiao

Assistant Professor,
Department of Integrative
Biology & Physiology, **UCLA**



Andreas Kogelnik

Founder and CEO, **Open Medicine Institute**



Marina R. Walther-Antonio

Assistant Professor of Surgery,
Mayo Clinic



Jose C. Clemente

Assistant Professor,
Department of Genetics and Genomic Sciences and the Icahn School of Medicine at Mount Sinai




Lynn M. Schriml

Associate Professor,
Epidemiology & Public Health,
Institute for Genome Sciences,
University of Maryland School of Medicine



Suzanne Devkota

Assistant Professor,
Director Microbiome
Research, **F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, UCLA**



A. Sloan Devlin

Assistant Professor,
Department of Biological
Chemistry and Molecular
Pharmacology, **Harvard Medical School**




Aleksandar D. Kostic

Assistant Professor, **Harvard Medical School**, Assistant Investigator, **Joslin Diabetes Center**



Hyun Jung Kim

Assistant Professor,
University of Texas at Austin




Yanjiao Zhou

Research Scientist, **The Jackson Laboratory**



Eric Huang

Professor, Department of
Dermatology, **University of California, San Diego**



Christopher Mason, PhD

Director, **MetaSUB International Consortium**



AJ Prussin, PhD

Charles E. Via, Jr. Department
of Civil and Environmental
Engineering, **Virginia Tech**




Jennifer Wargo

Assoc. Professor, Surgical
Oncology, **MD Anderson**



Jennifer M. Fettweis, Ph.D

Project Director, **Vaginal Human Microbiome Project**



Jessica Allegratti, MD, MPH

Instructor, **Harvard Medical School**, Director, Fecal Microbiota Transplant Program, **Brigham and Women's Hospital**



Stacy A. Kahn, MD

Director FMT Program, Dept.
Gastroenterology, Hepatology
and Nutrition, **Boston Children's Hospital**

The earlier you book, the more you save! Visit www.terrapiinn.com/microbiomeUS

NATIONAL BODIES



Paul E. Carlson Jr.

Principal investigator,
Laboratory of Mucosal
Pathogens and Cellular
Immunology, **CBER/OVRR,**
U.S. Food and Drug
Administration



Philip John (P.J.) Brooks

Program Director Division of
Clinical Innovation, **National**
Center for Advancing
Translational Sciences
(NIH)



Katherine Bowman

Senior Program Officer,
National Academy of
Sciences (NAS)



David Butler

Director, Office of Military and
Veterans Health, **National**
Academy of Sciences
(NAS)



Scott A. Jackson

Leader – Complex Microbial
Systems Group Biosystems
and Biomaterials Division,
National Institute of
Standards and Technology



Glen Satten

Senior Scientist, **Centers**
For Disease Control and
Prevention

BIOINFORMATICS



Zachary Kurtz

Scientist, **Lodo Therapeutics**
Corporation



Mehrdad Yazdani, Ph.D.

Machine Learning and Data
Scientist, **Open Medicine**
Institute, California Institute
for Telecommunications
and Information
Technology, UC San Diego



Yuriy Gusev, Ph.D.

Associate Professor, Innovation
Center for Biomedical
Informatics (ICBI),
Georgetown University
Medical Center



Raja Mazumder, Ph.D.

Associate Professor of
Biochemistry and Molecular
Medicine, **George**
Washington School
of Medicine & Health
Sciences



Jason Norman

Senior Scientist, **Vedanta**
Biosciences



Featured Presentations

PLENARY PANEL

REGULATIONS IN RESPONSE TO THE MICROBIOME

- How do you work with regulators in development of Microbiome treatments?
- How do you prevent Wild West scenarios where companies are promoting their product and operating without oversight?
- From FMT, Prebiotics to Probiotics, from food supplements to traditional treatments- what protocols must be established for such a wide variety of products?
- What standards are necessary and what does solid translational evidence look like in judging the efficacy of microbial treatments?



Paul E. Carlson Jr.

Principal investigator, Laboratory of Mucosal Pathogens and Cellular Immunology

CBER/OVRR, U.S. Food and Drug Administration



Matt Henn

Senior VP, Head of Drug Discovery and Bioinformatics

Seres Therapeutics



Alex Scheeler

Senior Regulatory Affairs Associate

OpenBiome



Kathleen Basmadjian

Senior Director, Global Regulatory Policy & Intelligence, Global Regulatory Affairs

Janssen R&D

PANEL

CUTTING THROUGH THE CONFUSION OF BIOINFORMATICS

- Why do our models seem to break down when ecology meets the worlds of statistics and medicine?
- How do we continue to identify stable sub communities?
- What bacterial interactions can we look to outside of our immediate field?



MODERATOR

Zachary Kurtz

Scientist

Lodo Therapeutics



Jim Brown

Director, Computational Biology, Senior Fellow

GlaxoSmithKline



Raja Mazumder

Associate Professor of Biochemistry and Molecular Medicine

George Washington School of Medicine & Health Sciences



Jason Norman

Senior Scientist

Vedanta Biosciences

08:50 **Chairperson's Opening Remarks**

TURNING RESEARCH INTO VIABLE THERAPEUTICS

09:00 **KEYNOTE ADDRESS**
The new paradigm of treatment - understanding the relationship between ecology and medicine in unlocking the potential of the microbiome

- What is the current state of the field and how have new techniques in molecular biology enabled us to probe the microbiome and better understand its diversity and biological significance?
- When dealing with living organisms- How does microbial ecology differ from classical drug therapies, and classical medical statistics?
- What areas have we seen greatest progress and how do we avoid overselling microbiome potential and current state before we have solid evidence of translational capacity?

Jack Gilbert, Faculty Director, **The Microbiome Center The University of Chicago**

10:00 **Speed Networking**

10:20 **Networking coffee break**

TRACK I: SCIENTIFIC

TRACK II: COMMERCIAL

INFECTIONS AND ANTIBIOTICS

CLINICAL TRIAL AND REGULATORY

11:00 **Re-assessing ethical issues in Microbiome research and medicine**

- How does the clinical approach change when patients can cheaply sequence their microbiome?
- Studies to advance personalized medicine will require broad public participation to provide sufficient material for biobanks.
- What implications does Microbiome Research have on our social and legal systems?

Andreas Kogelnik, Founder and CEO, **Open Medicine Institute**

FDA update
Points to consider Microbiome treatment development

- Understanding current guidelines for living biological samples.
- How are we addressing current challenges in developing microbial treatments?
- Regulatory implications of *C. Difficile*- microbiome- Host interactions.

Paul E. Carlson Jr., Principal investigator, Laboratory of Mucosal Pathogens and Cellular Immunology, CBER/OVRR, **U.S. Food and Drug Administration**

11:20 **Bugs as drugs for the skin: novel microbiome-based strategies for skin diseases**

- The skin microbiome is often overlooked the yet it plays a critical role in human health
- How are fluctuations in the skin microbiome associated with numerous diseases?
- Skin models in vitro and in vivo are imperfect in recapitulating the skin microbiome
- What novel strategies focused on the skin microbiome have shown promise in altering skin disease?

Travis Whitfill, Co-Founder, **Azitra**

Clinical innovations in Microbiome: From wellness to treatment

- The proper regulation of Microbiome is essential if the field is to be taken seriously as a viable treatment for diseases.
- What can we learn from proper design of clinical trials?
- How do we move away from the wild west like scene of dietary supplements?

PJ Brooks, Program Director, Director of Clinical Innovation, **National Center for Advancing Translational Sciences (NIH)**

11:40 **Skin Microbiome Editing**

- Dr. Huang's lab has established a Skin Probiotic Bank.
- How do you develop various carbohydrate-polymer conjugates as selective fermentation inducers (SFIs) for editing skin microbiome?
- Furthermore, fifty skin probiotic bacteria can be used as probiotics for treatment of more than twenty skin diseases including acne vulgaris.

Eric Huang, Professor, Department of Dermatology, **University of California, San Diego**

The great potential and limitations of the mouse model

- With mouse models being standard models why do we often see such varying results?
- What microbiome communities are essential to lab mice?
- Can cohabiting mice with common mice offer stronger research subjects that better replicate the human immune system?

Aleksandar D. Kostic, Assistant Professor, **Harvard Medical School**, Assistant Investigator, **Joslin Diabetes Center**

The earlier you book, the more you save! Visit www.terrapinn.com/microbiomeUS

12:00

ROUNDTABLES

Loss of Food Species

How is a reduction in Dietary diversity affecting our Microbiome?

FMT

Current state and future potential

Jessica Allegretti, Instructor, **Harvard Medical School**, Director, Fecal Microbiota Transplant Program, **Brigham and Women's Hospital**

Bioinformatics

Utilizing and translating microbiome data sets

Zachary Kurtz, Scientist, **Lodo Therapeutics Corporation**

Mouse Model

Potential and Limitations of mouse models

Aleksandar D. Kostic, Assistant Professor, **Harvard Medical School**, Assistant Investigator, **Joslin Diabetes Center**

Microbiome of the built environment

From research to application

Lynn M. Schriml, Associate Professor, Epidemiology & Public Health, Institute for Genome Sciences, **University of Maryland School of Medicine**

If you are interested in sponsoring the moderation of a roundtable contact Salvatore Manzo at +1 646 619 1798 or salvatore.manzo@terrapinn.com

12:40

Networking lunch



TRACK I: SCIENTIFIC

BIOINFORMATICS

2:00

Panel**Cutting through the confusion of Bioinformatics**

- Why do our models seem to break down when ecology meets the worlds of statistics and medicine?
- How do we continue to identify the stable sub communities?
- What bacterial interactions can we look to outside of our immediate field?

Moderator**Zachary Kurtz** Scientist, **Lodo Therapeutics Corporation****Jim Brown**, Director, Computational Biology, Senior Fellow, **GlaxoSmithKline****Raja Mazumder**, Associate Professor of Biochemistry and Molecular Medicine, **George Washington School of Medicine & Health Sciences****Jason Norman**, Senior Scientist, **Vedanta Biosciences**

2:20

2:40

Teaching Computers to recognize the sick gut

- What advantages do Machine learning offer us in Microbiome?
- How do you train systems to identify Healthy bacteria communities?
- What relationships are we looking for as we are rarely looking at just one molecule?

Mehrdad Yazdani, Machine Learning and Data Scientist, **Open Medicine Institute, UC San Diego**

TRACK II: COMMERCIAL

DRUG DEVELOPMENT- BIOMARKER

Developments of Targeted Therapy via Microbiome Community

- The level of uniqueness in the microbiome make up means far more
- How can we enhance sampling protocols with high quality metagenomic data?
- How in depth must we go to identify key bacteria of interest?
- With current treatments having wide ranging responses in patients- How personalized does each treatment need to be?

Carrie (McManus) Brodmerkel, Head, Immunology Biomarkers, Immunology Therapeutic Area, **Janssen R&D****How precisely targeted drugs are changing the behaviour of the microbiome**

- With the billions of possible microbes the task of identifying and verifying a positive lead is key to effective drug development.
- With bacterial communities being so specific to regions how do we optimize best combinations?
- How can we take advantage of Synthetic Biotics to enhance and encourage healthy interactions?

Aoife Brennan, Chief Medical Officer, **Synlogic****Gut-on-a-Chip, changing the future of PV for the Microbiome**

- A microphysiological human intestine model
- *In vitro* host-gut microbiome ecosystem and long-term maintenance
- Modeling intestinal diseases to validate therapeutic interventions

Hyun Jung Kim, Assistant Professor, **University of Texas at Austin**

TRACK I: SCIENTIFIC

GUT MICROBIOME AND EARLY LIFE

3:00

C-section delivery and the criticality of Vaginal microbiome in allergies, and immune disorder

- How influential is early microbiota on later life events?
- Can we re-introduce the vaginal microbiome to C-section babies to avoid averse immune disorders, and allergies?
- What effects are we seeing over the long term in c-section children?
- Could this be the new and healthier standard for delivering newborns?

Jose C. Clemente, Assistant Professor, Department of Genetics and Genomic Sciences and the Immunology Institute, **Icahn School of Medicine at Mount Sinai**

TRACK II: COMMERCIAL

MICROBIOME NUTRITION

Personalized Nutrition for the Microbiome

- With microbiome and nutrition becoming more synergistic how close are we to moving prediction and prevention with dietary changes?
- Looking at current data- How can we interpret the current state of individualized microbiome responses to various foods and healthy and diseased states?
- What does this mean for the future of food and for the treatment landscape?

Suzanne Devkota, Assistant Professor, Director Microbiome Research, **F.Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute**, Assistant Professor-in-Residence, **David Geffen School of Medicine, UCLA**

3:20

A chemical understanding of the Gut Microbiome

- Uncovering how and why bacteria metabolize bile acids?
- How do these bile acids influence biological processes?
- How can we make use of this to better monitor and alter bacterial metabolism in vivo?

A. Sloan Devlin, Assistant Professor, Department of Biological Chemistry and Molecular Pharmacology, **Harvard Medical School**

The Elite Athlete Microbiome: What makes top Athletes so unique?

- How Can we utilize next-generation sequencing to understand what makes elite athletes unique?
- What changes are we seeing pre and post sport activity?
- What does this mean in the next generation of athletes?
- Are we seeing key markers for endurance, fatigue and recovery?
- How can this be used to aid the wider population?

Jonathan Scheiman, Co-Founder CEO, **FitBionics**

3:40

If your company has a leading solution or approach related to the gut microbiome or obstetrician related microbiome studies, then you can sponsor this session by contacting Salvatore Manzo at +1 646 619 1798 or salvatore.manzo@terrapinn.com

Harnessing nature to help farmers sustainably feed the planet

- How do we increase agricultural activity while not relying on technology of the high yields gains of the past?
- What is being done to isolate the endophytes of various plants and how can this improve drought resistance, nutrient absorption, etc?
- What real-life examples have we seen of the benefits of these enhanced food and crops?

Barry Goldman, Vice President, Discovery, **Indigo Agriculture**

4:00

Networking coffee break

DEVELOPMENT COLLABORATION

4:40

KEYNOTE ADDRESS**Identify partnerships in the emerging microbiome Industry**

- How and why is each party involved in a transaction? How have you defined critical roles of support?
- How do the therapeutic area and stage of development affect the financial valuation?
- How do small and large companies bridge the gap between approaches to asset and financial valuation?

Cosmas Giallourakis, Director R&D, **Takeda**

5:00

KEYNOTE ADDRESS**A large pharma perspective on the microbiome**

- How does Pfizer evaluate opportunities in the microbiome?
- What developments in the field is Pfizer monitoring most closely?
- What capabilities does Pfizer consider most valuable in biotech partners?

Nikola Trbovic, Director, R&D Technology Strategy, **Pfizer**

5:20

Chairperson's Closing Remarks

5:30

Drinks reception

EVOLVING MICROBIOME INDUSTRY

09:00

KEYNOTE ADDRESS

From discovery to clinical – SYN-004 (ribaxamase) protects the gut microbiome from antibiotic-mediated damage

- Importance of maintaining a healthy gut microbiome — when faced with the threat of antibiotics, strategies include to protect, repair, or replace the gut microbiota.
- Discussion of ribaxamase as a means to protect the microbiome from beta lactam antibiotics.
- Ramifications beyond the individual.

Michael Kaleko, Senior Vice President, Research & Development, **Synthetic Biologics**

09:20

KEYNOTE PANEL

Regulations in response to the Microbiome

- How do you work with regulators in development of Microbiome treatments?
- How do you prevent Wild West scenarios where many companies are promoting their product and operating without oversight?
- From FMT, Prebiotics to Probiotics, from food supplements to traditional treatments- what protocols must be established for such a wide variety of products?
- What standards are necessary and what does solid translational evidence look like in judging the efficacy of microbial treatments?

Paul E. Carlson Jr., Principal investigator, Laboratory of Mucosal Pathogens and Cellular Immunology, **CBER/OVRR, U.S. Food and Drug Administration**

Matt Henn, Senior VP, Head of Drug Discovery and Bioinformatics, **Seres Therapeutics**

Alex Scheeler, Senior Regulatory Affairs Associate, **OpenBiome**

Kathleen Basmadjian, Senior Director, Global Regulatory Policy & Intelligence, Global Regulatory Affairs, **Janssen R&D**

10:00

If your company is a leader in Microbiome R&D then you can sponsor this session by contacting Salvatore Manzo at +1 646 619 1798 or salvatore.manzo@terrapinn.com

10:20

Speed Networking

10:40

Networking coffee break

TRACK I: SCIENTIFIC

TRACK II: COMMERCIAL

WOMEN'S HEALTH

COMMERCIALIZATION INVESTMENT LANDSCAPE

11:20

The vaginal microbiome during pregnancy and the postpartum period

- What differences do we see in the vaginal microbiome throughout pregnancy?
- Does the composition and structure of the pregnancy vaginal microbiome influence susceptibility to adverse pregnancy outcomes?
- Why are there such large differences across women of different ethnicities?

Marina R. Walther-Antonio, Assistant Professor of Surgery, **Mayo Clinic**

PANEL

Securing funding from multiple sources – how to continuously show value to pharma, venture capital, and grant programs

Micah Mackison, VP Corporate Development and Strategy, **Assembly Biosciences**

Rodolphe Clerval, Chief Business Officer, **Enterome Bioscience**

Henry Rath, VP Business Development, **Seres Therapeutics**

11:40

The functionality of the vaginal microbiome

- Examining the roles of the women's urogenital conditions, physiological states, environmental factors and host genetic components to the structure and composition of the vaginal microbiome
- Investigating the role of the vaginal microbiome in pregnancy and the peripartum period in full-term and preterm pregnancies
- Characterizing and comparing the genomes of previously uncharacterized species of importance to women's reproductive health
- What states of the vaginal microbiome are protective?

Jennifer M. Fettweis, Project Director, Vaginal Human Microbiome Project, **Virginia Commonwealth University**

12:00

The Critical role of the Early Microbiome in Childhood health and development

- Commense is developing approaches to guide the priming, seeding, and maintaining of the microbiome in infants and children.
- Can nurturing a healthy microbiome early in life represent a novel strategy to significantly reduce the impact of diseases?
- What insights can we gain from natural exposures to beneficial microbes?
- How can physicians, and product developers take advantage of these finds to develop a novel category of products to address critical unmet needs in pediatric populations?

James Mutamba, Co-Founder, **Commense Health**

Accelerating and optimizing phage therapy in human health to enhance the microbiome

- How is the rebirth of American Phage therapy able to influence the Microbiome?
- How is Epibiome able to produce fully automated viral and bacterial identification for phage cocktails?
- What are the opportunities in not just human, but food, and animal?

Nick Conley, President & CEO, **Epibiome**

12:10

ROUNDTABLES

Vaginal Microbiome

How do we establish "Normal" and "healthy" ecosystems?

Marina R. Walther-Antonio, Assistant Professor of Surgery, **Mayo Clinic**

Immunology

Optimizing the gut microbiome to support and protect the immune system

Reserved For Host Therabiomics

The gut-brain axis

The other information superhighway

Elaine Hsiao, Principal Investigator, Hsiao Lab, **UCLA**
Yanjiao Zhou, Research Scientist, **The Jackson Laboratory**

Translating environmental microbiome

What can we learn from microbial interactions in various environments that can aid us in understanding the human microbiome and developing treatments?

Ross Youngs, CEO, **Biosortia**
Zachary Kurtz, Scientist, **Lodo Therapeutics**

Nutrition

Advent of the microbiome and the next generation of nutrition in our everyday life

Jonathan Scheiman, Co-Founder CEO, **FitBiomics**

If you are interested in sponsoring the moderation of a roundtable contact Salvatore Manzo at +1 646 619 1798 or salvatore.manzo@terrapinn.com

12:50 **Networking lunch**

TRACK I: SCIENTIFIC

TRACK II: COMMERCIAL

GUT BRAIN AXIS AND IMMUNOTHERAPY

BUILT ENVIRONMENT

2:10 **The microbiota modulates gut physiology and behavioral abnormalities associated with autism**

- How can observation of Gut Brain Axis help inform us of ASD?
- Can extended-duration treatment protocol be a promising approach to alter the gut microbiome and virome?
- Does reversal of Autism like symptoms in mice mean Microbiome transplant treatments?

Elaine Hsiao, Principal Investigator, Hsiao Lab, **UCLA**

Microbiome of the Built Environment: From Research to Application

- How can we examine the formation and function of microbial communities in built environments?
- What are the impacts of such communities on human health?
- How do humans shape complex indoor microbiomes?

Lynn M. Schriml, Associate Professor, Epidemiology & Public Health, Institute for Genome Sciences, **University of Maryland School of Medicine**

2:30 **The Microbiome and Multiple Sclerosis**

- How can the Gut Microbiome shape host immunity and communicate with CNS via Gut Brain Axis?
- What microbes, genes and metabolites have been identified that protect from autoimmunity?
- How does the gut microbiome affect treatment efficiency of MS drugs in Mouse models?

Yanjiao Zhou, Research Scientist, **The Jackson Laboratory**

The Metagenomic and Metadesign of Subways and Urban Biomes

- How can we improve city utilization and planning through the detection, measurement, and design of metagenomics within urban environments?
- How can these baseline profiles be used to identify potential bio-threats, and provide an additional level of data, that can even aid in Smart City Capabilities?

Christopher Mason, Director, **MetaSUB International Consortium**

2:50 **The extreme personalization potential in microbiome and Immunotherapy**

- How are the trillions of bacteria in our bodies creating unique individual makeups?
- Are drug immunotherapies reacting to the microflora of our gut?
- What promising efforts have been made to align with immunotherapy?

Jennifer Wargo, Assoc. Professor, Surgical Oncology, **MD Anderson**

Architectural design for health and wellness

- What does it mean when structures are not just environmentally sustainable but actually benefit the health of their inhabitants and communities?
- How do building materials and finishes relate to human and environmental health?
- How can you scale “Restorative design” from the individual, to building, to community, to global?

If your company provides solution for “microbiome-conscious” built-in environment than you can sponsor this session by contacting Salvatore Manzo at +1 646 619 1798 or salvatore.manzo@terrapinn.com

SKIN, ORAL, AND LUNG

3:10 If your company provides solution for “microbiome-conscious” built-in environment than you can sponsor this session by contacting Salvatore Manzo at +1 646 619 1798 or salvatore.manzo@terrapinn.com

3:30 **Transforming the Therapeutic Landscape for Atopy and Asthma**

- Focusing on the design of a mixed-species therapeutic microbial consortium to treat airway inflammation.
- How do you leverage multi-scale next-generation microbiome analyses to develop and test microbial-based therapeutics for induction and maintenance of immune tolerance?
- How can we use the microbiome to drive patient stratification and tailored microbial therapeutics?

Nikole Kimes, Founder, Vice President, **Siolta Therapeutics**

3:50 **Chairperson’s Closing Remarks**

4:00 **End of conference**

The earlier you book, the more you save! Visit www.terrapinn.com/microbiomeUS

Pitch & Partner

As Microbiome treatment moves from buzzword to reality, discovery, development, and commercialization are becoming more critical. Coupled with this shift is a flood of capital into new and established biopharma and diagnostics companies, as investors and venture capitalists become an increasingly important source of funding for the most important breakthroughs in Microbiome.

The lack of a platform for these investors and their potential clients has contributed to the launch of Pitch & Partner at the World Microbiome Congress Americas 2017. Pitch & Partner will enable new and old pharma and biotech companies to pitch their microbiome innovations in front of an audience of VCs and investors, as well as exposing them to successful case studies of past funding ventures.

The list of investors and investees will be released shortly, but we can reveal that the track will open with an exclusive panel session on how to secure funding in today's crowded pharma environment.

PANEL SESSION

Securing funding from multiple sources – how to continuously show value to pharma, venture capital, and grant programs



Micah Mackison

VP Corporate Development &
Strategy

Assembly Biosciences



Rodolphe Clerval

Chief Business Officer
Enterome Bioscience



Henry Rath

VP Business Development
Seres Therapeutics

Networking

USE JUJAMA TODAY TO MAXIMISE YOUR EVENT EXPERIENCE!

Microbiome World Congress Americas 2017 recognizes the importance of networking.

JUJAMA offers a unique service, combining the latest in networking software with a personal touch to provide an easy-to-use approach for you to facilitate quality networking opportunities.

MAKING THE MOST OF THE EVENT WITH JUJAMA

JUJAMA is our full service app that allows you to manage your time efficiently and effectively at the event, while ensuring you meet all the right people.

You can use the app to set meetings, explore the agenda, familiarize yourself with speakers and exhibitors and much, much more. Log into your profile, update your details and get started. It's that simple!

Networking with Jujama is available 24/7, enabling you to plan and get the most out of the event well in advance. Accessible via numerous devices, you can:

- Review the latest exhibitor list and see where booths are on the floorplan
- Contribute to specific groups and start conversations long before the event
- Share relevant content with your social networks

As an event attendee, you'll get access to your FREE event management profile and will get personalized login details to use the app.

Business Matching at the event goes live four weeks before the show.

Any queries contact jessie.sampson@terrapinn.com

Note: Jujama respects your privacy and assures you that all of your personal contact information will be kept confidential. Rest assured that no contact information will be shared via our platform.



EVENT PARTNERS



10

reasons to attend

- 1** The **only** microbiome conference in North America focusing on **both the scientific and commercial opportunities** in the field
- 2** Keynote case studies from **microbiome game-changers** such as **Jack Gilbert** whose pioneering metagenomics work and extensive study of the dynamics of thousands of microbial environments has shaped the modern Microbiome field.
- 3** Hear from the **FDA** on the many hurdles to consider when developing microbiome-based treatments
- 4** Cut through the confusion on **bioinformatics** with an exclusive panel and roundtable hosted by **Zach Kurtz**, with leaders from **George Washington School of Medicine & Health Sciences, UC San Diego, Georgetown University Medical Center** and **GlaxoSmithKline**
- 5** Navigate the Wild West of microbiome regulations: with a one of a kind panel of regulatory experts including the **FDA, OpenBiome, Seres Therapeutics** and **Janssen's** Senior Director of Global Regulatory Affairs
- 6** Go **beyond the gut** with groundbreaking case studies on **skin, brain, oral and vaginal microbiome** for a full view of the clinical opportunities in the field
- 7** Find out how to navigate the risky world of funding as the leading biotechs of **Assembly Bio Sciences, Enterome** and **Seres Therapeutics** show attendees how to demonstrate value to pharma, venture capitalists and grant programs
- 8** Preview the game-changers of the future with case studies on everything from the unique athlete microbiome (**FitBiotics**), to the game changing "Gut on a Chip."
- 9** **Witness innovation in the making** with a **Pitch & Partner** breakout stream, where biotechs will highlight the opportunities of the future and investors will make them happen
- 10** You will have full access to the co-located **World Precision Medicine Congress** in Washington D.C., meaning a 2-for-1 opportunity to usher your work into the next generation of personalized medicine, and health!

Register now

The earlier you book, the more you save! Reserve your spot today!

For the latest price see
www.terrapinn.com/microbiomeUS

DELEGATE BOOKING					
	TIER 1 18 AUG	TIER 2 9 SEPT	TIER 3 29 SEPT	TIER 4 20 OCT	FINAL
2 DAY CONFERENCE PASS	\$2,025	\$2,100	\$2,250	\$2,360	\$2,475
GROUP OF 3+	\$1,620	\$1,680	\$1,800	\$1,880	\$1,980

BOOK NOW

Register at www.terrapinn.com/microbiomeUS

Or call + 1 212 379 6320

BRING YOUR TEAM

With two days packed full of great content and networking opportunities, you can't possibly cover it all alone!

Bring your team and get an extra discount.
Call +1 212 379 6320